Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Noxopharm Ltd. ( (AU:NOX) ) just unveiled an announcement.
Noxopharm Limited has received approval from the Human Research Ethics Committee to commence the HERACLES clinical trial, marking a significant milestone for the company. This trial, the first of its kind in Australia, will test SOF-SKN™, a novel drug candidate targeting chronic inflammatory diseases, including cutaneous lupus erythematosus. The approval allows Noxopharm to begin recruitment and operational activities, collaborating with the Doherty Clinical Trials team in Melbourne. This development underscores Noxopharm’s strategic focus on leveraging Australian expertise in early-phase clinical trials and securing federal R&D tax benefits, potentially enhancing its market position in the biotech industry.
More about Noxopharm Ltd.
Noxopharm Limited (ASX:NOX) is a clinical-stage Australian biotech company focused on discovering and developing novel treatments for cancer and inflammation. The company leverages its specialist in-house capabilities and strategic partnerships to build a pipeline of proprietary drugs based on two technology platforms: Sofra™ for inflammation, autoimmunity, mRNA drug enhancement, and oncology, and Chroma™ for oncology.
Average Trading Volume: 84,187
Technical Sentiment Signal: Sell
Current Market Cap: A$19.58M
For a thorough assessment of NOX stock, go to TipRanks’ Stock Analysis page.